🇺🇸 FDA
Patent

US 11701341

Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease

granted A61KA61K31/415A61K9/0053

Quick answer

US patent 11701341 (Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease) held by MEREO BIOPHARMA 1 LIMITED expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MEREO BIOPHARMA 1 LIMITED
Grant date
Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/415, A61K9/0053, A61P, A61P11/00